Differentiated design is at the core of the ... UltraCAR-T assets with the only difference being a unique transposon targeting a specific antigen for each UltraCAR-T asset. This set-up allows ...

AT03-65 is designed to target advanced, recurrent ... a proprietary linker payload platform to advance a pipeline of differentiated ADC candidates aimed at addressing key unmet medical needs.

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors ...

AT03-65 is a recombinant anti-CLDN6 monoclonal antibody conjugated to AxcynDOT™, a proprietary payload developed by Axcynsis with a differentiated mechanism of action and broad anti-cancer activities.

AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism ... AT03-65 is designed to target advanced, recurrent, or metastatic CLDN6+ solid tumors ...